Receptor for activated C-kinase 1 regulates the cell surface expression and function of ATP binding cassette G2

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2320-2328

  Ikebuchi, Yuki ^a   Ito, Kousei ^a   Takada, Tappei ^a   Anzai, Naohiko ^b   Kanai, Yoshikatsu ^c   Suzuki, Hiroshi ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BREAST CANCER RESISTANCE PROTEIN; CHLOROQUINE; ESTRONE SULFATE; FUMITREMORGIN C; MESSENGER RNA; MITOXANTRONE; RECEPTOR FOR ACTIVATED C KINASE 1;

ARTICLE; CELL MEMBRANE RESISTANCE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE VESICLE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE; ESTRONE; GTP-BINDING PROTEINS; HELA CELLS; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING;

EID: 78649573304     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034603     Document Type: Article

References (41)

1. Berns H, Humar R, Hengerer B, Kiefer FN, and Battegay EJ (2000) RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J 14:2549-2558.
2. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
3. Cao XX, Xu JD, Xu JW, Liu XL, Cheng YY, Wang WJ, Li QQ, Chen Q, Xu ZD, and Liu XP (2010) RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat 123:375-386.
4. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
5. Evseenko DA, Paxton JW, and Keelan JA (2007) Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35:595-601.
6. Haimeur A, Conseil G, Deeley RG, and Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5:21-53.
7. Hayashi H, Takada T, Suzuki H, Akita H, and Sugiyama Y (2005) Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11. Hepatology 41:916-924.
8. Huang CC, Liu CH, and Chuang NN (2008) An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras. Int J Biochem Cell Biol 40:423-431.
9. Ikebuchi Y, Takada T, Ito K, Yoshikado T, Anzai N, Kanai Y, and Suzuki H (2009) Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4. Hepatol Res 39:1091-1107.
10. Imai Y, Ishikawa E, Asada S, and Sugimoto Y (2005) Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65:596-604.
11. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, and Sugimoto Y (2002) Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97:626-630.
12. Kiely PA, O'Gorman D, Luong K, Ron D, and O'Connor R (2006) Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and β1 integrin to promote cell migration. Mol Cell Biol 26:4041-4051.
13. Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, and Ochiai A (2009) Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 65:105-111.
14. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21:1895-1903.
15. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, and Schuetz JD (2004) The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218-24225.
16. Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, and Peters GJ (2008) Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 123:1712-1720.
17. + exchange regulatory factor. J Biol Chem 277:22925-22933.
18. Lipsky NG and Pagano RE (1985) A vital stain for the Golgi apparatus. Science 228:745-747.
19. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113 (Pt 11):2011-2021. (Pubitemid 30386505)
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-267.
21. McCahill A, Warwicker J, Bolger GB, Houslay MD, and Yarwood SJ (2002) The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol 62:1261-1273.
22. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764.
23. Minami S, Ito K, Honma M, Ikebuchi Y, Anzai N, Kanai Y, Nishida T, Tsukita S, Sekine S, Horie T, et al. (2009) Posttranslational regulation of Abcc2 expression by SUMOylation system. Am J Physiol Gastrointest Liver Physiol 296:G406-G413.
24. Mochly-Rosen D, Khaner H, and Lopez J (1991) Identification of intracellular receptor proteins for activated protein kinase C. Proc Natl Acad Sci USA 88:3997-4000.
25. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, and Walsh K (2003) Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278:39068-39075.
26. Mohrmann K, van Eijndhoven MA, Schinkel AH, and Schellens JH (2005) Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 56:344-350.
27. Nagashio R, Sato Y, Matsumoto T, Kageyama T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang SX, and Okayasu I (2010) Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer 69:54-59.
28. Noguchi K, Katayama K, Mitsuhashi J, and Sugimoto Y (2009) Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 61:26-33.
29. Orbán TI, Seres L, Ozvegy-Laczka C, Elkind NB, Sarkadi B, and Homolya L (2008) Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter. Biochem Biophys Res Commun 367:667-673.
30. Ortiz DF, Moseley J, Calderon G, Swift AL, Li S, and Arias IM (2004) Identification of HAX-1 as a protein that binds bile salt export protein and regulates its abundance in the apical membrane of Madin-Darby canine kidney cells. J Biol Chem 279:32761-32770.
31. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50.
32. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61:3-13.
33. Ruan Y, Guo L, Qiao Y, Hong Y, Zhou L, Sun L, Wang L, Zhu H, Wang L, Yun X, et al. (2009) RACK1 associates with CLEC-2 and promotes its ubiquitin-proteasome degradation. Biochem Biophys Res Commun 390:217-222.
34. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, et al. (2000) Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60:2589-2593.
35. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447.
36. Szatmari I, Vámosi G, Brazda P, Balint BL, Benko S, Széles L, Jeney V, Ozvegy-Laczka C, Szántó A, Barta E, et al. (2006) Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 281:23812-23823.
37. Takada T, Suzuki H, Gotoh Y, and Sugiyama Y (2005a) Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos 33:905-909.
38. Takada T, Suzuki H, and Sugiyama Y (2005b) Characterization of polarized expression of pointor deletion-mutated human BCRP/ABCG2 in LLC-PK1 cells. Pharm Res 22:458-464. (Pubitemid 40558505)
39. Wakabayashi-Nakao K, Tamura A, Furukawa T, Nakagawa H, and Ishikawa T (2009) Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. Adv Drug Deliv Rev 61:66-72.
40. Wakabayashi K, Nakagawa H, Tamura A, Koshiba S, Hoshijima K, Komada M, and Ishikawa T (2007) Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J Biol Chem 282:27841-27846.
41. Zhang W, Cheng GZ, Gong J, Hermanto U, Zong CS, Chan J, Cheng JQ, and Wang LH (2008) RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem 283:16416-16426.